

Welcome, Introductions, and Review Agenda

Jean Slutsky, PA, MSPH

Chief Engagement and
Dissemination Officer

Sue Sheridan, MIM, MBA, DHL

Director of Patient Engagement

Charlotte W. Collins, JD

Chair
Compensation Subcommittee

Darius Tandon, PhD

Chair
Evaluation Subcommittee



Conflict of Interest Statement

Disclosures of conflicts of interest of members of this panel are publicly available on PCORI's website and are required to be updated annually. Members of the Advisory Panel Patient Engagement (PEAP) are also reminded to update conflict of interest disclosures if the information has changed by contacting Rachel Melo.


If the PEAP will deliberate or take action on a matter that presents a conflict of interest for you, please inform the chair so we can discuss how to address the issue. If you have questions about conflict of interest disclosures or recusals relating to you or others, please contact Rachel Melo.



Agenda

- 10:30 a.m. Welcome, Introductions and Review Agenda
- 11:00 a.m. Evaluation Update
- 12:00 pm. Lunch
- 12:45 p.m. Group photo
- 1:00 p.m. Session with Communication and Dissemination Research (CDR) Panel
- 2:30 p.m. Break
- 2:45 p.m. Rethinking the Pipeline
- 3:15 p.m. PEAPs in Action
- 4:30 p.m. Discussion & Wrap-up
- 5:00 p.m. PEAP Meeting Adjourned





Welcome

Glad you're here!

John Chernesky Patient/Caregiver/Patient Advocate

Emily Creek Patient/Caregiver/Patient Advocate

Libby Hoy Patient/Caregiver/Patient Advocate

Megan Lewis Researchers

Suzanne Madison Patient/Caregiver/Patient Advocate

Ting Pun Patient/Caregiver/Patient Advocate

John Westfall Clinician

David White Patient/Caregiver/Patient Advocate




New Engagement Dissemination & Implementation Staff Introductions



Chris Gayer, PhD
Program Officer
Dissemination and
Implementation



Kristen DeCaires, MPH
Program Associate
Dissemination and
Implementation



Arielle Gorstein, MPH
Program Associate
Dissemination and
Implementation



Merit Review



Whitney McInvale, MPH
Program Associate

National Urban Fellows

Tania Guaman



Jacqueline Gannon



Evaluation Update

Laura Forsythe, PhD, MPH

Associate Director, Evaluation and Analysis



PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE

Agenda

- Incorporating PEAP feedback in the PCORI Evaluation Framework
- Recent results: Learnings about research engagement
 - Effects of engagement on the project
 - Effects of engagement on the partners
 - PCOR principles in action
- Discussion & recommendations



Incorporating PEAP Feedback in the PCORI Evaluation Framework




Incorporating PEAP Feedback in the PCORI Evaluation Framework

- Revised evaluation framework graphics, particularly regarding the impacts of engagement in research , to increase clarity




PCORI's Overall Evaluation Framework “Original” Format




Original



PCORI's Overall Evaluation Framework



Evaluation Framework: Engagement in Research “Original” Format



Original



Evaluation Framework: Engagement in Research

Patient-Centered CER

Engagement in Research

- Who
- What
- When
- How
- Influence
- Principles



Studies that Matter to Patients

- Changes to research questions, process, design, & outcomes
- Study participant experiences
- Recruitment & retention
- Study quality
- To whom and how results are disseminated
- Trust in information
- Understanding of information

GOALS

Useful Information

↓

Use of Information

↓

Influence Others



IMPACT

Health Decisions

↓

Health Care

↓

Health Outcomes



Incorporating PEAP Feedback in the PCORI Evaluation Framework

- Revised evaluation framework graphics, particularly regarding the impacts of engagement in research, to increase clarity
- Evaluation questions that can be answered now or soon are prioritized
- Measuring diversity of applicants and awardees

In the longer-term, we are:

- Exploring ways to include engagement metrics in the PCORI dashboard
- Considering ways to measure diversity among Merit Reviewers, Peer Reviewers, etc.
- Identifying ways to assess PCORI awardee engagement of patients in future projects funded by others



Incorporating PEAP Feedback in the PCORI Evaluation Framework

Assessing the Development of the PCOR Community

- Refined this evaluation question: “What is effect of PCORI’s unique approach to building a *skilled* PCOR Community?”
- Ensured language reflected both patients and other stakeholders throughout
- Evaluating both whether PCORI is building community, and the effectiveness of that community
- Including metrics for attendees at PCORI workshops and events, and recipients of PCORI communications
- Assessing perceptions of value of partner input from both researchers and partners



Incorporating PEAP Feedback in the PCORI Evaluation Framework

Assessing the Impact of Engagement in Research

- Current priorities include:
 - Assessing relevance of research from the perspective of patients and caregivers
 - Comparing PCORI studies to those of other funders
 - Understand relationship between patient engagement and study rigor
 - Learning about engagement for dissemination, and sharing those learnings widely

In the longer term , we are:

- Exploring options for software platforms that allow tracking of online access to study products and tools
- Considering ways to work with patient organizations and PPRNs/CDRNs to assess views about usefulness and relevance of the PCORI portfolio



Incorporating PEAP Feedback in the PCORI Evaluation Framework

Assessing PCORI's Influence

- Including examples of PCORI influence on the broader healthcare eco-system (beyond healthcare research)

In the longer term, we are:

- Considering ways to capture PCORI influence on clinical practice



Example of PCORI Influence Beyond Research

(1 of 2)

Dr. Sharron Close (July 2016)

- The PCORI Engagement Award *“Family & Science: Bidirectional Translation of Knowledge and Need in Sex Chromosome Aneuploidy”* was funded to:
 - Build stakeholder community engagement to direct research toward outcomes that matter to them;
 - Plan family and scientific conferences;
 - Expand awareness of X & Y chromosome variations; and
 - Assist in the design of new intervention studies
- Dr. Close reports that the project has **led to unexpected outcomes beyond research.**



Example of PCORI Influence Beyond Research (2 of 2)

- Listening to patients' needs led to a recognition that only some patient-important outcomes could be addressed through research. The team's response to these needs led to:
 - Increasing Awareness about X & Y Variations (official state of Georgia Proclamations declaring an Awareness Day and an Awareness Month (policy change))
 - Establishing the first Southeast Regional X & Y Support Group
 - Creation of a new regional multidisciplinary clinic "The eXtraordinarY Kids Clinic of Atlanta"
 - Development of educational materials for physicians, schools, insurers and the justice system

"The engagement process has indeed empowered patients and families to change not only research and patient-centered outcomes, but also to expand awareness and knowledge that may influence policy to their benefit." Dr. Close




Recent Results: Learnings about Research Engagement

- Impact of engagement on the project
- Impact of engagement on the partners
- PCOR principles in action




Information Sources on Engagement in Research



Literature Repository on Research Engagement

- Searchable and sortable
- Tagged for phase of research, communities engaged, PCORI funding



PCORI Awardee Articles as Case Studies

Engaging stakeholders to design a comparative effectiveness trial in children with uncontrolled asthma

Kim Erwin^{*1}, Molly A Martin², Tara Flippin¹, Sarah Norell¹, Ariana Shadlyn¹, Jie Yang¹, Paula Falco¹, Jaime Rivera¹, Stacy Ignoffo³, Rajesh Kumar⁴, Helen Margellos-Anast⁵, Michael McDermott⁶, Kate McMahon⁷, Giselle Mosalm⁸, Sharmilee M Nyenhuis², Valerie G Press⁹, Jessica E Ramsay⁵, Kenneth Soyer¹⁰, Trevonne M Thompson² & Jerry A Krishnan^{2,11}


Journal of Comparative Effectiveness Research



Contents lists available at ScienceDirect

Contemporary Clinical Trials

journal homepage: www.elsevier.com/locate/conclintrial



Using patient engagement in the design and rationale of a trial for women with depression in obstetrics and gynecology practices[☆]



Ellen Poleshuck ^{a,b,*}, Marsha Wittink ^a, Hugh Crean ^c, Tara Gellasch ^d, Mardy Sandler ^e, Elaine Bell ^a, Iwona Juskiewicz ^a, Catherine Cerulli ^a




Recent Results: Evaluation of Research Engagement

- Effects of engagement on the project
 - Effects of engagement on the partners
 - PCOR principles in action



Method 1: Cross-sectional Content Analysis

(N = 258 awardees, 254 partners)



What are common engagement activities?

Researchers & Partners reported partner activities in the last year
(N = 258 awardees, 254 partners)

Partners

Shared personal perspective (e.g., priorities, experiences)

Awardees

Received confirmation on aspects of study

Guidance and feedback about research project processes and materials

Decision-making role about research project processes and materials

Direct participation in conduct and dissemination (e.g., recruiting participants, collecting data, presenting)



In what ways is engagement making a difference?

Themes from qualitative data analysis (N = 258 awardees, 254 partners)

Awardees

- Refined aspects of the study
 - Catalyst for research question
 - Interventions or comparators
 - Outcomes and measurement
 - Data collection processes
 - Recruitment/retention processes
- Increased patient-centeredness
 - Interventions or comparators
 - Outcomes & data collection processes
 - Recruitment materials
- Enhanced enrollment rates

**All themes found in >10% of responses about that phase, themes in green found in >25%*



In what ways is engagement making a difference?

Themes from qualitative data analysis (N = 258 awardees, 254 partners)

Awardees


- **Refined aspects of the study**
 - Catalyst for research question
 - Interventions or comparators
 - Outcomes and measurement
 - Data collection processes
 - Recruitment/retention processes
- **Increased patient-centeredness**
 - Interventions or comparators
 - Outcomes & data collection processes
 - Recruitment materials
- **Enhanced enrollment rates**

Partners

- Understanding partner perspectives
- **Refined aspects of the study**
 - Research question
 - Interventions or comparators
 - Outcomes and measurement
 - Recruitment/retention processes
- **Increased patient-centeredness**
 - Interventions or comparators
 - Outcomes
 - Recruitment materials
- **Enhanced enrollment rates**
- **Interpretation of results**




Method 2: Longitudinal Content Analysis (N = 13 projects)



Longitudinal Analysis: Effects of Engagement (Case #13)

Awardee Ratings of Partner Influence



A great deal
A moderate amount



A small amount
None



Phases of Research Project

Interventions & Comparators

“

We gave our opinion on **what information families would like** to have available to them...what order the information should be presented, ...**The team was able to tweak the presentation to make it more user friendly.**

– Caregiver/Family Member




Phases of Research Project



Outcomes & Measurements

“ [I] discussed my priorities with researchers. They described how they would measure those issues.
-Payer (public or private insurance)

“ All stakeholders assisted us in deciding on important outcomes to measure...
This input resulted in our primary medical outcome being disability days at one year after treatment. -Awardee





Study Participant Recruitment & Retention

“

We brainstormed ways to **change their approach so that families are more at ease...**they changed how they reach out to patients based on feedback.

We discussed why families might choose to withdraw from the study and ... about better ways to communicate with families that are involved in the study. [As a result], **more families stayed in the study.** – *Caregiver/Family Member*



“

These changes **increased enrollment in the trial from 65% to 95% and increased retention from 58% to 85%.** -*Awardee*

Phases of Research Project



PCOR Principles in Practice



Our success in achieving these goals stems in part from involving stakeholders throughout the entirety of the project, **building strong ongoing relationships, fostering open communication, and appreciating all opinions.** - *Awardee*



Our child enjoyed that the researchers asked for her thoughts and opinions and **took her input seriously.** – *Caregiver/Family Member*



We got together quarterly as a team, we shared a meal together and sat at a big round table where we were asked and given the opportunity to express our thoughts, ideas and opinions. **Everyone was given the chance to share and respond.**

– *Caregiver/Family Member*

Phases of Research Project



PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE

Research Topics
& Research
Questions

Interventions &
Comparators

Outcomes &
Measurement

Other Aspects of
Study Design

Study Participant
Recruitment &
Retention

Data Collection

Data Analysis &
Results Review

Dissemination

Recent Results: Evaluation of Research Engagement

- Effects of engagement on the project
- **Effects of engagement on the partners**
- PCOR principles in action



Most Common Effects of Engagement on Partners

- **Established new relationships**
- **Improved personal health management**
- **Made a difference in the lives of others**
- Personal growth or self-improvement
- Gained new knowledge and insights about research
- New professional opportunities
- Belief in patient/stakeholder representation in research



Effects of Engagement on Partners: Established New Relationships

“ Our patient and family **panel has become a ‘family’**. We care about each other and what each and every one is going through!

– Patient/consumer



Effects of Engagement on Partners: Improved Personal Health Management

“ Understanding the various health disparities leading to diabetes, kidney disease **has made me assess my personal life, my level of physical activity and my food intake. I have made changes in my lifestyle** which include exercising 3 x per week and encouraging my family to take part in physical activities such as hiking, basketball and so forth... **This was an eye opener.**

—Other type of Stakeholder

“ Patients I've been working with have taught me to be a better patient, to self advocate. – *Caregiver/Family Member*



Effects of Engagement on Partners: Made a Difference in the Lives of Others

“ As an ‘older’ citizen, with mobility limitations, **this involvement has allowed me to ... contribute "to the better good"**. Although I have personal medical issues and challenges, ... doing what I can in my very limited capacity to improving opportunities for broader patient involvement in healthcare decision making and the shaping of healthcare to reflect patient needs.

– *Patient/Consumer*



Recent Results: Evaluation of Research Engagement

- Effects of engagement on the project
- Effects of engagement on the partners
- **Examples of PCOR principles in action**



PCOR Principles in Action: Reciprocal Relationships

“

When we started the project the...team took the time to explain the big picture and **everyone's role in the project**.

– Representative from Clinic/Hospital/Health System



PCOR Principles in Action: Co-learning

“

Even though I knew my vocabulary wasn't up to medical par, and research was brand new to me, I truly do understand that it is my "voice" as a patient and caregiver that is my contribution to the. Anytime I offered a suggestion during our weekly team meetings, they were welcomed and compassionately responded to.

– *Caregiver/Family Member*

“

They have a rich storehouse of experiences to help guide our projects.

-Awardee



PCOR Principles in Action: Partnerships (1 of 2)

“

We share ideas openly. No one takes it personal if we disagree. We all come with different perspectives and **we respect each other's opinions and are committed to working together for the best outcomes.**

– *Caregiver/Family Member*

“

We got together quarterly as a team, we shared a meal together and sat at a big round table where we were asked and given the opportunity to express our thoughts, ideas and opinions. Everyone was given the chance to share and respond. They were also very respectful of our time.

– *Caregiver/Family Member*



PCOR Principles in Action: Partnerships (2 of 2)

“ Having the round table discussions where every persons ideas were valued equally was really important. It made it so that everyone was more willing to share honestly because they weren't intimidated or made to feel that the doctors/researchers knew better than we as parents/caregivers did.

-Caregiver/family member

“ **Demonstrating that [partners'] opinions have been incorporated have increased their perception of the value of engagement.** For example, stakeholders were shown the final patient activation tool and they were pleased that their suggestions were taken into account. In addition, a quarterly update is sent to stakeholders regarding the progress of the study and how their suggestions have impacted the study. *-Awardee*



PCOR Principles in Action: Trust, Transparency, & Honesty

“ We have shared trust and honesty with the team by **sharing our honest opinions and receiving their honest opinions in return**. In addition, I feel that the **team truly cares** about our family. Our daughter was at the hospital for a different reason, not involving the study, and members of the team sent her well wishes while she was in the hospital.

—Patient/Consumer

“ Our success in achieving these goals stems in part from involving stakeholders throughout the entirety of the project, **building strong ongoing relationships, fostering open communication, and appreciating all opinions**. -Awardee



Discussion

- Which findings are most meaningful to you?
- What else do you want to know about the effects of engagement on PCORI projects? On the partners?



Lunch with CDR

12:00-12:45pm



*At 12:45 please meet at
the registration desk
for a group photo*

Dissemination Opportunities at PCORI

Lia Hotchkiss, MPH

Director, Eugene Washington PCORI Engagement Awards

Bill Lawrence, MD, MS

Senior Program Officer, Communication and Dissemination Research

Chris Gayer, PhD

Program Officer, Limited Competition Dissemination and Implementation



Background

- There is a gap between what we know optimizes healthcare delivery and what actually gets implemented in everyday practice (Green et al., 2009)
- It takes years for new evidence from clinical research to influence health care (Balas, 2000)
- PCORI authorizing legislation recognized this issue and charged us with addressing it

Green LW, Ottoson JM, Garcia C, Hiatt RA. Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annu Rev Public Health. 2009;30:151–174. doi: 10.1146/annurev.publhealth.031308.100049.

Balas EA, Boren SA. Managing clinical knowledge for health care improvement. In: Bemmel J, McCray AT, editors. Yearbook of Medical Informatics 2000: Patient-Centered Systems. Stuttgart, Germany: Schattauer Verlagsgesellschaft mbH; 2000:65-70.



Authorizing Legislation

“The purpose of the Institute is to **assist patients, clinicians, purchasers, and policy-makers in making informed health decisions** by advancing the quality and relevance of evidence concerning the manner in which diseases, disorders, and other health conditions can effectively and appropriately be prevented, diagnosed, treated, monitored, and managed **through research and evidence synthesis...**

... and the dissemination of research findings with respect to the relative health outcomes, clinical effectiveness, and appropriateness of the medical treatments, services...”

-- from PCORI’s authorizing legislation



Dissemination and Implementation Program


Using PCORI Research to Improve Healthcare

What is the goal of the D&I Program?

- The D&I Program is charged with heightening awareness of the results of PCORI-funded research, and with advancing efforts to put these findings into practice to improve healthcare delivery and health outcomes.



PCORI D&I Activities Overview



Key D&I Initiatives Underway

TRANSLATION

- PCORI submits all research findings to peer review before releasing them.
- Once peer review is complete, the Dissemination & Implementation Program oversees the translation of these findings into accessible and comprehensible summaries:
 - one targeting patients and the general public
 - one for a professional audience.
- These 500-word abstracts, prepared by PCORI's Patient-Centered Outcomes Research Translation Center, are posted on pcori.org.
- PCORI's website along with other materials describing the study and its results.



Key D&I Initiatives Underway

PROMOTING ACCESS TO PUBLISHED PCORI RESEARCH FINDINGS

- PCORI stipulates that manuscripts be deposited to PubMed Central so that they are available to all.
- To promote even faster availability of findings, PCORI works with journals to pay the open access fees for articles that report key findings in peer-reviewed journals.



Eugene Washington PCORI Engagement Award Program: Focus on Dissemination

Lia Hotchkiss, MPH

Director, Eugene Washington PCORI Engagement Award Program



Engagement Award Program Overview

- Programmatic funding opportunity, launched in Feb 2014
- Supports projects that will build a community better able to participate in PCOR/CER and serve as channels to disseminate study results
- Engagement Award projects will produce deliverables that are useful to awardees, PCORI, and the broader PCOR community for increasing patient and stakeholder engagement in PCOR/CER



Engagement Awards

Engagement Award (EA) projects

- build our knowledge base about how patients and other stakeholders want to participate in PCOR/CER or receive research findings;
- implement training or skill development initiatives to build capacity for engaging in PCOR/CER; and/or
- strengthen channels for disseminating PCOR/CER findings.

Engagement Award Initiative Notice (EAIN) meetings/conferences

- align with PCORI's mission and strategic plan, and facilitate expansion of PCOR/CER in areas such as:
 - research design and methodology
 - research development
 - dissemination and implementation

Awards of **up to \$250,000** per project, up to **two years** in duration



Emphasis On Planning for Dissemination of PCOR Findings

- Organizations with strong ties to end-user audiences
- To prepare to disseminate and implement PCOR/CER results
- Focus on strengthening infrastructure, relationships and approaches to actively disseminate and implement research results or products derived from PCORI studies or other high-quality PCOR/CER findings consistent with PCORI's research priorities
- Separate from PCORI Limited D&I funding opportunity
- Infrastructure, relationships and approaches developed must be sustainable with the potential to be scaled
- Information and tools generated must be generalizable and made public



Examples of Projects of Interest

Processes



- Place existing or emerging PCOR/CER research results within the context of the body of evidence in the topic area identified.
- Develop, demonstrate, and evaluate the **processes** necessary to incorporate research results from these studies into decision-making settings of your population.

Collaborations



- Establish multi-stakeholder **collaborations** to ID effective pathways and approaches for reaching a target audiences for disseminating a set of PCOR/CER research results on a topic relevant to your organization's mission.
- Propose and develop strategies and tools necessary to implement them. Test and refine the strategies.

Approaches



- Design innovative **approaches** to actively disseminate PCOR/CER findings that are oriented to your target population.
- Demonstrate that approaches reach your audience and describe strategy for how approaches would be used to improve uptake of findings.

Funded Engagement Awards with Dissemination Focus



“Improving Care for Critically Ill Patients & Families Through Research Dissemination/Implementation”

Challenge

- Focusing on patients' needs and preferences requires that healthcare clinicians have knowledge of PCOR and can implement the findings in clinical practice.

Objectives

- Engage patients and caregivers to participate in PCOR-based initiatives;
- Develop a learning collaborative for disseminating and implementing PCOR;
- Design an “e-community” learning network to engage clinicians, patients, and families to share strategies for enabling PCOR to improve care.



*Ruth Kleinpell, PhD, RN
Society of Critical Care Medicine*

Project Collaborators:
Rush University Medical Center/Center for Clinical Research and Scholarship; and Patient & Family National Advisory Board Members

*Engagement Award Project,
awarded December 2015*



“Reducing Cancer Disparities by Engaging Stakeholders”

Objectives

- Develop a learning community with a common agenda related to reducing cancer screening-related disparities;
- Determine disparities in screening rates;
- Identify evidence-based approaches that increase screening and reduce screening disparities;
- Adapt effective intervention approaches for use in primary care practices;
- Disseminate a model approach to intervention adaptation in health systems;
- Evaluate learning community engagement and related outcomes.



Ron Myers, PhD

Thomas Jefferson University

Project Collaborators:
Two regional health systems (Lehigh Valley Health Network and Delaware Valley Accountable Care Organization); a patient and stakeholder advisory committee from each health system; insurers; a state and a local health department; regional employer groups; a national advocacy organization; a regional advocacy organization; and Children's Hospital of Philadelphia

*Engagement Award Project,
awarded October 2015*



PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE

“PCOR Dissemination at Work: How Employers Use Evidence to Make Employee Health Investment Decisions”

Objectives

- Identify existing PCOR/CER evidence of high relevance to a working population
- Understand how employers use such evidence
- Improve the uptake and implementation of this PCOR-based evidence in employee health investment decision-making

Methods

- Employer case studies, expert panel, employer interviews, stakeholder-specific communications materials, and dissemination events



*Kimberly Jinnett, PhD
The Center for Workforce
Health and Performance*

Project Collaborators:
*Integrated Benefits Institute; Center
for Value-Based Investment Design;
RAND; employers*

*Engagement Award Project,
awarded May 2016*



What We've Funded



Patient-Centered Outcomes Research Institute

BLOG

NEWSROOM

SUBSCRIBE

CAREERS

CONTACT

 Search



ABOUT US

FUNDING OPPORTUNITIES

RESEARCH & RESULTS

GET INVOLVED

MEETINGS & EVENTS

Research & Results

WHAT WE'VE FUNDED

RESEARCH PROJECTS

PROGRAM PROJECTS

RESEARCH WE SUPPORT

HOW WE SELECT RESEARCH TOPICS

RESEARCH METHODOLOGY

PCORNET: THE NATIONAL PATIENT-CENTERED CLINICAL RESEARCH NETWORK

RESEARCH DISSEMINATION AND IMPLEMENTATION

What We've Funded

Learn more about the key terms on this page ▾

Results 1 - 10 of 152 | [Download these results in CSV format](#)

Engaging Stakeholders to Build Infrastructure for PCOR in the Primary Care Safety Net

Organization: Morehouse School of Medicine

Project Type: Program project

Year Awarded: 2016

Engaging Stakeholders for a Patient-Centered Research Agenda for Chronic Kidney Disease in Delaware

Current Search

Program project

Engagement Award

You also can see a list of the Program Projects we've funded. Just remove the "Research Project" filter above.

[RESET ALL FILTERS](#)

Refine Your Results

Enter keyword(s)

[SEARCH PROJECTS](#)

Next Steps

- Emphasize desire for future Engagement Awards to focus on preparing for dissemination of PCORI research findings
 - Continue to refine guidance on PCORI website
 - Work with Dissemination and Implementation team to promote PCORI's dissemination funding opportunities
 - Discuss dissemination ideas with key stakeholders to explore potential fit for Engagement Award funding



Thank you

Contact Information:

Lia Hotchkiss, MPH

Program Director, Eugene Washington PCORI Engagement Awards

Patient-Centered Outcomes Research Institute (PCORI)

1828 L Street, NW 9th Floor

Washington, DC 20036

Telephone: 202-494-3441

Email: lhotchiss@pcori.org

Visit: <http://www.pcori.org/funding-opportunities/programmatic-funding/eugene-washington-pcori-engagement-awards>



Communication and Dissemination Research (CDR)

William Lawrence, MD, MS

Senior Program Officer, Communication and Dissemination Research



CDR Team



Jean Slutsky
Chief Engagement and
Dissemination Officer



Bridget Gaglio
Senior Program Officer



Michelle Henton
Program Associate



Aisha Hussain
Program Assistant



Kim DiGioia
Program Associate



Bill Lawrence
Senior Program Officer



The Research We Fund Is Guided by Our National Priorities for Research



**Assessment of
Prevention, Diagnosis,
and Treatment Options**




**Improving Healthcare
Systems**



**Communication and
Dissemination Research**



Addressing Disparities



**Accelerating PCOR and
Methodological
Research**



PCORI Mission Statement

PCORI helps people make informed healthcare decisions, and improves healthcare delivery and outcomes, by producing and promoting high-integrity, evidence-based information that comes from research guided by patients, caregivers, and the broader healthcare community.



Importance of CDR

Producing information is not enough.

- Clear communication approaches and active dissemination of findings to all audiences, in easy to understand formats, are critical to increasing the awareness, consideration, adoption, and use of research by patients, caregivers, and healthcare providers
- In other words, information itself is of little use unless:
 - It reaches those who need it
 - It is clear and comprehensible



CDR Funding Objective

The CDR program seeks to fund comparative effectiveness research (CER) that:

- directly compares two or more efficacious health communication and dissemination interventions or strategies
- that engage patients, caregivers, and providers
- in the context of real-world clinical-care settings and situations
- to enable patients and caregivers to make the best possible choices among available options for care and treatment



CDR Funding Priorities

Focus on **CER** in the following three key areas:

1. **Communication strategies** to promote the use of health and healthcare CER evidence by patients and clinicians
2. **Dissemination strategies** to promote the use of health and healthcare CER evidence by patients and clinicians
3. **Explaining uncertain health and healthcare CER evidence** to patients and clinicians



Communication and Dissemination Research

Available Funds: Up To \$8 Million

Total Direct Cost Per Project : \$1.5 million

Maximum Project Period: 3 years



Current Portfolio



Number of Projects:

44

Amount Awarded:


\$75.7 million

Number of states
where we are funding
research:

21



Portfolio by Disease/Condition



* Other includes: Diabetes (1), CT Scan Radiation Dose (1), Rare Genetic Disorders (1), etc.



Thank You!



PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE

D&I Limited Competition PFA

Chris Gayer, PhD

Senior Program Officer, Limited Competition Dissemination and Implementation



Purpose and Objectives

- ***Purpose:*** This announcement gives PCORI awardee teams an opportunity to propose **investigator-initiated** strategies for disseminating and implementing findings from their PCORI funded studies
 - propose the next step(s) for making their research results and any corresponding product(s) more useful, actionable, accessible and available to targeted end users



D&I Activities We Aim to Fund

- We seek to fund projects:
 - designed to **actively** disseminate and implement research results and products
 - using approaches that are informed and guided by established dissemination and implementation models and frameworks
 - in real world settings
- This mechanism **does not** support passive dissemination strategies
 - Manuscript writing and publication
 - Scientific conference support



Supported D&I Activities

1. Develop, demonstrate, and evaluate approaches for **incorporating PCORI research results in specific decision-making settings**
2. **Adapt the content, format, or vehicle for delivering CER research evidence**, to improve its use for different populations and across settings.
3. Take results and products found effective “**to scale**” in diverse settings and populations.
4. **De-implement** or reduce the use of interventions that are not evidence-based, have been prematurely widely adopted, or are harmful or wasteful.

Note: All D&I projects must **actively disseminate/implement findings to targeted end users and evaluate the success of the dissemination and implementation strategy**.



2016 Application Cycles by the Numbers

	Cycle 1	Cycle 2	Cycle 3
LOIs Received	19	5	12
Full Applications Received	6	5	?
# Proposed for Funding	<i>In process</i>	n/a	?

- *D&I funding slates are approved by the Chief Engagement and Dissemination Officer.*
 - *Cycle 1 approvals in early November*
- **Eligibility:** PCORI must be in receipt of PCORI draft final research reports corresponding to the PCORI funded research study prior to submission of full application
- *PCORI DFRR's received to date = 15*



Questions?



PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE

15 Minute Break

Rethinking the Pipeline (P2P)

Courtney Clyatt

Program Officer

October 19, 2016



Seeking Guidance from PEAP

- Are the overarching goals of the P2P still relevant?
- Are the P2P near term goals of developing PCOR capacity (as defined in our evaluation framework) still a priority for PCORI?
- What more do we need to know to determine the ideal structure of Pipelines going forward (i.e.: Are all three tiers valuable/necessary)?
- Is our current evaluation framework providing PCORI with the relevant information to determine “success” based on the P2P goals?
- What are the options for the structure of P2P going forward?



Overarching Goals of P2P

- Enabling the non-researcher community (including individual patients) to drive partnership development and research project (flip the funding)
- Developing research partnerships, infrastructure and a diverse, skilled PCOR community especially in underserved and underrepresented communities
- Creating a robust Dissemination and Implementation network that recognizes the PCORI brand
- Submission of high quality PCOR/CER proposals to PCORI and other funders with strong engagement plans
- Learning about promising pre-engagement practices and methods in the P2P (P2P as a learning laboratory) and share with broader research community



Current Progressive Pipeline



Tier I – Pre-Engagement/Community Projects

Awardees can be patients, stakeholders or researchers. By the end of the Tier they must form a partnership with someone from a different category – e.g.: patient awardee must form partnership with researcher, researcher awardee must form partnership with patient, stakeholder awardee must form partnership with patient and researcher. Awardees must identify CER ideas.

Tier II – Partnership and Infrastructure Development Projects

Awardees must be a research partnership team. By the end of the Tier awardees will have identified CER questions in preparation for a research proposal.

Tier III Proposal Development Projects

Awardees are research partnerships who will work on crafting their CER proposals during the award period. By the end of the project period they will have submitted an LOI for a PFA and will have completed an Engagement Plan for a research project.



P2P - Strengthening PCOR Nationwide

Number of projects awarded:

Tier I – 123

Tier II – 71

Tier III - 22

Amount awarded:


\$4.7 Million

**(Tier I Cycles 1, 2 & 3 and
Tier II Cycles 1 & 2, Tier
III Cycle 1)**

**Number of states where
we are funding projects:**

**37 states, District of
Columbia and Puerto
Rico**

As of July 1, 2016



Outputs/Achievements from P2P

- 216 projects have yielded more than 1,000 partnerships
- 71 out of 76 Tier I projects met their deliverables and advanced to Tier II
- 22 out of 27 Tier II projects were funded for Tier III awards
- 2 Tier II projects submitted an LOI for a Research PFA and were invited to submit a full proposal
- 1 Tier II project was awarded a PCORI research project; awardee submitted for a PFA while in Tier II. All 22, Tier III Cycle 1 projects are required to submit an LOI by 3/8/17
- More than 700 project leads and partners trained on: PCOR
 - PCORI 101 –History, Mission, and Vision
 - PCOR/CER
 - Applying to PCORI
 - Merit Review Criteria
 - Methodology Standards
 - Meaningful Engagement
 - PCOR Guiding Principles
 - Engagement Rubric



Examples of Organizations with P2P Awards *

Patient Stakeholder Organizations	Hospital Systems	Universities and Research Centers	
• Beautiful You MRKH Foundation	• Children's Mercy Hospital	• Adelphi University	• University of Nevada-Las Vegas
• Center for Practical Bioethics	• Columbia Gorge Family Medicine	• Billings Clinic Center for Clinical Translational Research	• University of North Carolina-Chapel Hill
• CysticLife	• Department of Orthopaedic Surgery, Hospital for Joint Diseases, NYU Langone Medical Center	• Georgetown University	• University of Rochester
• Dravet Syndrome Foundation		• Georgia Center for Oncology Research and Education	• University of South Florida
• F.O.C.U.S. Greater Syracuse, Inc.	• Henry Ford Health System	• GW Cancer Institute, GW School of Medicine	• University of Southern California
• Family Voices	• Miners' Colfax Medical	• Loma Linda University	• University of Utah School of Medicine
• Family-Run Executive Director Leadership Association (FREDLA)	• Palo Alto Medical Foundation	• Medical University of South Carolina	• Washington State University College of Nursing
• Hudson River HealthCare, Inc.	• Patient-Centered Primary Care (PCPC) Team, K-6 Adult Medicine Clinic, Highland Hospital"	• Minneapolis Medical Research Foundation	• Wayne State University
• National Association of School Nurses	• Seattle Children's Hospital	• New Mexico State University	
• National Fibromyalgia and Chronic Pain Association	• Sutter Health, University of Utah	• Northeastern University	
• National Council of La Raza/CSULB Center for Latino Community Health, Evaluation and Leadership Training		• Northwestern University	
• National Psoriasis Foundation		• The Board of Trustees of the University of Illinois	
• SolSurvivors		• Tufts University	
• Spina Bifida San Diego		• Tulane University	
• St. Anna's Episcopal Church		• UC Davis Medical Center, Section of General Thoracic Surgery	
• The Sickle Cell Association of New Jersey		• University of Arkansas for Medical Services	
• Zero Breast Cancer		• University of Colorado Denver - College of Nursing	
		• University of Florida Board of Trustees	
		• University of New Mexico	

*this list is not inclusive of all awarded organizations/individuals




Independent Tier III



Awardees are established research partnerships who will work on crafting their CER proposals during the award period. By the end of the project period they will have submitted an LOI for a PFA and will have completed an Engagement Plan.



Evaluating the Pipeline to Proposal Awards



We hypothesize that Pipeline to Proposal Awards will **promote capacity for PCOR** (e.g., organizational structures, resources, collaborative relationships, policies, procedural protocols, and commitment to patient-centeredness needed to conduct PCOR). Moreover, we expect that this capacity will **lead to future PCOR** which will ultimately have a scientific and clinical impact.



Evaluation Activities

2015 - Contracted with AIR to answer the following:

1. Are these investments successful in fostering partnerships?
2. What are some elements of successful partnership structures?
3. Did these partnerships embody the PCOR Engagement Principles?
4. To what extent did this project prepare Awardees to pursue research funding from PCORI or another funder?

2016 – Contracted with AIR to address the following:

1. How did these partnerships among patients, stakeholders, and researchers embody the PCOR Engagement Principles?
2. What additional, crosscutting, themes from the Tier I, Cycle 1 analysis were apparent among the Tier I, Cycle 2 responses?
3. What new themes were identified among responses from Tier I, Cycle 2 awardees and partners?

Are there other questions that the PEAP would like answered?



PCOR Principles in the Pipeline (as Reported by Tier I Cycle 2 Awardees)

Co-learning

- “There is a **lot to learn about how a study is worked**, numbers needed, testable and who we might need to assist us” (Patient)

Reciprocal Relationships

- “Relationship building is vital and time consuming. The partnership development piece in itself is a **significant endeavor** and we are very thankful to PCORI for providing us the opportunity to focus on establishment of Governance and Stakeholder Engagement/Communication” (Researcher)
- “Very important to create a **sense of team** - Important to have **relationship building** experiences - Very important to have someone directly in charge of making sure **families/patients feel connected and heard**” (Researcher)

Trust/Transparency/Honesty

- “The PI had to go out and find these partners...and carefully did so and worked to build relationships first. This has led to a great amount of goodwill and **trust** and respectful team work in this first part of Tier 2.” (Researcher)

Partnership Building

- **Partnership** takes a whole lot of **work and time**, but the final results are **more reliable** and reflect the views of more than one individual. Partners bring **different assets** to the group which help tremendously with the project” (Clinician)



Next Steps

What should be the next step in the pipeline?

- Continue “as is” and launch a new progressive cycle in 2017?
- Only launch another Independent Tier III in 2017?
- Launch another Cycle AND an Independent Tier III in 2017?
- Make Tier III Competitive
- Redesign/Streamline Tiers



Length of the Pipeline




2016 PCORI
2015 PCORI
2014 PCORI

2017 PCORI
2018 PCORI



Competitive Tier III



Streamlining the Pipeline Combining Tiers I & II with a Competitive Tier III



ေပါဒ္ဒန
NCDRI



Engagement Resources may help streamline proposal-development process

- **PCORI's "Engagement Rubric"**

<http://www.pcori.org/sites/default/files/PCORI-Engagement-Rubric-with-Table.pdf>

- **Sample Engagement Plans**

<http://www.pcori.org/sites/default/files/PCORI-Sample-Engagement-Plans.pdf>

- **PCORI Compensation Framework**

<http://www.pcori.org/sites/default/files/PCORI-Compensation-Framework-for-Engaged-Research-Partners.pdf>

- **Engagement in Research website page**

<http://www.pcori.org/content/engagement-research>

- **PCORI's Methodology Standards PC-1 to PC-4**

<http://www.pcori.org/assets/PCORI-Methodology-Standards1.pdf>



Seeking Guidance from PEAP

- Are the overarching goals of the P2P still relevant?
- Are the P2P near term goals of developing PCOR capacity (as defined in our evaluation framework) still a priority for PCORI?
- What more do we need to know to determine the ideal structure of Pipelines going forward (i.e.: Are all three tiers valuable/necessary)?
- Is our current evaluation framework providing PCORI with the relevant information to determine “success” based on the P2P goals?
- What are the options for the structure of P2P going forward?



Discussion

PEAPs in Action

John Chernesky – Consumer Engagement in Spinal Cord Injury Research at the Rick Hansen Institute

Lorraine Johnson – LymeDisease.org

Anjum Khurshid – Children's Comprehensive Care Clinic

Megan Lewis – Delphi Panel Study

Regina Greer Smith – Pastors4PCOR and CAPriCORN CDRN Patient Clinician Advisory Council

Jack Westfall – High Plains Research Network Community Advisory Council





Pastors4PCOR

Building the Capacity of Faith-based Communities to Engage in Health Research Initiative:

Pastors4PCOR (P4P) Celebration of Research Ministry Ambassadors

October 1, 2016, Chicago, IL

Dr. Rebecca Johnson

Northwestern University

Dr. Diana Ingram

Rush University Medical
Center

Dr. Paris Davis, Executive Director, Triedstone Total Resource CDO
Regina Greer-Smith, MPH, LFACHE, S.T.A.R. Initiative



How it all began



**Academic
Partner**

"A community advocate and faith-based partners focused on the promise that PCOR (patient centered outcomes research) holds for underserved communities and joined an activated faith-based partner seeking social justice in healthcare and answers to its community health status" -Regina Greer-Smith



CHICAGO, ILLINOIS

Short Distances to Large Gaps in Health

Follow the discussion

#CloseHealthGaps

Life expectancy at birth (years)

Shorter Longer

1 mile



Red Line

Green Line

Orange Line

72 YRS
EAST GARFIELD PARK

KEDZIE

UNITED
CENTER

81 YRS
LINCOLN PARK

LINCOLN
PARK ZOO

85 YRS
LOOP

WILLIS
TOWER

79 YRS
GAGE PARK

WESTERN

MIDWAY INT'L
AIRPORT

69 YRS
WASHINGTON PARK

GARFIELD

MUSEUM OF
SCIENCE AND
INDUSTRY

© 2015 Robert Wood Johnson Foundation



Center on
Society
and Health

Robert Wood Johnson
Foundation

Homewood
Chicago
10/1/2016

Road map to healthy communities

Health Outcomes



Life expectancy data Chicago

Illinois and Cook County data

Faith based communities

Health Factors







Pastors4PCOR: Engaging Faith-based Communities



Guiding Principles

- Partners commit to open and honest communication
- Major decisions are made inclusively and information is shared
- Partners communicate study back to their own communities in meaningful and usable ways

Pastors4PCOR's Mission

"To increase the participation of underserved communities of color in comparative effectiveness research and patient centered outcomes research through the design, development and implementation, reporting and dissemination of research."

We will achieve this by:

- ✓ Fostering relationships to build a robust research infrastructure in the church communities; and
- ✓ Building the capacity of faith-based communities to engage in health research.
- ✓ Partnering with researchers from academic research centers;



P4P BOARD OF DIRECTORS

First Name	Last Name	Board Role	Affiliations
Simon	Gordon	Advisory Board Chairman	Bishop, Triedstone Baptist Full Gospel Church
Walter	Turner III	Advisory Board Co-Chairman	Senior Pastor – New Spiritual Light Church
Paris	Davis, PhD, MBA	Executive Director	Total Resources Development Corporation- Triedstone Baptist Full Gospel Church
Rebecca	Johnson, PhD	Advisory Board Member Academic partner	Buehler Center for Aging, Health & Society, Feinberg School of Medicine Northwestern Memorial Hospital
Regina	Greer-Smith, MPH, LFACHE	Advisory Board Member Community Advocate	Healthcare Research Associates, LLC S.T.A.R. Initiative
Diana	Ingram, PhD, MPH	Advisory Board Member Academic partner	Rush University Medical Center
Gennadyi	Voronov, MD	Advisory Board Member Health care systems	John H. Stroger Hospital of Cook County Health and Hospitals System
Ralph	Martire	Advisory Board Member Community Advocate	Center for Tax and Budget Accountability (CTBA)
Beverly	Rogers, BA, CWA	Advisory Board Member Community	Community Member – Caregiver Advocate Jeremiah Community Outreach Services
Dena	Craig	Advisory Board Member Community	Media



Pastors4PCOR


Research Ministry Ambassadors and Project

Team






Our Journey Completed!





Faithbased community health survey

Distribution of survey participants



Pastors4PCOR

"To help inspire and engage congregations in research through education."

466 people from 11 faith based communities across South Chicagoland responded to our survey.

79% were women and 21% were male.

99% were African American

55% college educated
39% high school diploma
6% less than high school

Surveys were developed and administered by Research Ministry Ambassadors as part of training for Research Ministry.



11% caregiver



7% Veteran



7% homeless



0-499



500-999




Over 1,000




57% employed





73% retired



01 / DEMOGRAPHICS



Priority Health Conditions: Survey Results



Health Factors and Resources: Survey Results

Question 3: Which health related factors should faith based communities focus on?






Chart shows responses of 20% or higher.

Question 4: Health factors faith based communities should focus on first




In your opinion where should we start?

Question 5: What are the resources your faith based community needs to address the health conditions and factors you have identified?



Resources needed to support faith-based community efforts to improve health

Occupational experience



Faith based community members and the health industry



Things We Learned Together While Developing P4P Network:

Successes

- Open lines of communication
- Working relationships
- Complement of skills and personalities
- Finding funds to sustain project
- New partnerships

Challenges

- Time
- Getting to know each others processes and infrastructure
- Mapping the geography of faith based communities



Things we learned together about Engaging Faith-based Communities with Health Research:

Successes

- Support from pastors
- Growing confidence of learners
- Learner enthusiasm and engagement
- Community based IRB certification
- New partnership opportunities for individuals and churches

Challenges

- Time for support and mentoring
- Difficult for participants to attend every step
- Finding time when everyone can attend meetings
- Engagement research is time consuming
- Research is temporary and no substitute for health services



Key Project Deliverables

- ✓ 11 Churches members of P4P Network
- ✓ 14 Trained RMAs
- ✓ 100% RMAs IRB Certified

Pastors4PCOR 10/1/2016

- ✓ 3-5 Health Factors Identified
- ✓ 3-5 Health Conditions Identified
- ✓ Partnership with Health Research Team Agreed



Research Ministry Next Steps



Planning your year...

Pastors4PCOR Research Ministry 2016

JANUARY

MAY

SEPTEMBER

FEBRUARY

JUNE

MARCH

JULY

APRIL

AUGUST

RMA
Graduation!

ADAPTABLE
E Partnership

*Plan to Attend
RMA 2017
Quarterly Meetings!*

*Letter of Intent
for EA Award:
Train the Trainer*

*Work with
Another
RMA!*

*Schedule
Forum*



P4P and ADAPTABLE ANSWERS for BETTER CARE

Results of this study will help patients and their caregivers answer questions like:

- How much aspirin should I take each day to reduce my risk of another heart attack or stroke?
- Do the benefits of taking aspirin every day differ based on the dose?
- Do the risks differ based on the dose?
- Based on my health, age, and other circumstances, what's the best dose to protect my health?

This study will use the power of PCORnet to seek answers to these questions and improve patient care and outcomes.




Identifying the aspirin dose that works best could prevent as many as

88,800
deaths per year
worldwide



Other Tools to Sustain Research Ministry

- Research Ministry Ambassador Alumni meeting – February/March 2017
- Pastors4PCOR Priority Health Year



Research Ministry Ambassador Pledges, Session #5

“One thing I liked about the session is that I have a Pledge to help my church and community with health issues!”

I pledge to schedule an educational / informational forum by November, 2016.



I pledge to help raise men's awareness about the importance of participating in Health Research.



I pledge to become more involved in community-based/faith-based research activities.



I pledge to work with others to assist his/her church in health fairs.
(Commit to at least 1 RMA!)



I pledge to do more research networking on the PCORI website.



I pledge to participate in ADAPTABLE.



I pledge to seek out others to come and join Pastor4PCOR.



I pledge to be an Ambassador for Health Education for Seniors. (Healthy Eating, Exercise, etc.)

I have been energized to take things forward in my faith-based community Health Ministry.



Research Ministry Ambassador Certificate

GRADUATION CELEBRATION HELD ON OCTOBER 1 2016, TRIEDSTONE





Research Ministry Ambassador Certificate

GRADUATION CELEBRATION HELD ON OCTOBER 1 2016, TRIEDSTONE CHURCH





Contact Information

Project Lead

Dr. Paris Davis email: drpdavis77@gmail.com

Research Ministry Ambassador Trainers

Regina Greer-Smith email: healthcareresearch@sbcglobal.net

Dr. Rebecca Johnson email: rebecca.johnson@northwestern.edu

Dr. Diana Ingram email: diana_ingram@rush.edu

Patient-Centered, Story-telling App for Complex Needs Children

Rahel Berhane, MD
Anjum Khurshid, MD PhD
October 21, 2016

Challenges

- Health care delivery system relegates patients to passive recipients of care
- Health care technology shortcomings inhibit engagement
 - Fragmented stories – data siloes
 - Information overload
 - Institutional culture –Data blocking
 - Privacy – Legal hurdles

Objectives

- Design and implement a patient-centered community health data ecosystem in a pediatric multidisciplinary care clinic
- Evaluate use rate and its effectiveness in enhancing patient engagement and self management

Comprehensive Care Clinic

- Two separate programs
 - Medical Home for medically fragile children
 - “Clinic without walls” – Community based program for children with behavioral complexity

Project Plan

- Phase I
 - Define the project as “ Collaborative Story telling”
 - Design a prototype
- Phase II
 - Define a governance structure for data ecosystem
 - Develop a platform for data aggregation
- Phase III
 - Implement “ Collaborative Story telling” application
 - Evaluate outcomes
- Phase IV
 - Scale up to a community-wide platform
 - Engaged patients/caregivers participate in research collaboration

Partners and Stakeholders



Technology Partners

- Theresa Neil Strategy and Design
- Cloud Forest Solutions
- Privacera



Stakeholders

- Parents of children in CCC clinic
- Providers and case managers at CCC
- Managed Care Organizations (Superior, BCBS)
- Community (AISD; Family Resource Center)
- School nurses
- DME/Home health/Therapy agencies


Day 1: Family Perspective



Day 1: Family Perspective




Day 2: Extended Care Circle Perspective



Day 3: Primary Care Provider Perspective



Day 4: Family-Provider Relationship



Insights and Themes

- Need to take the onus off the family for being the only one holding and sharing the big picture.
- A synthesized story pulled from different sources can ensure greater transparency & accountability
- Without trust, families will not share the important personal aspects of their story
- An integrated story-based view will help providers understand the patient and family situation before they walk in the room
- Fit the storytelling into the natural flow of families lives by leveraging the tools they already use (mobile phones)



Patient Story

Mobile application

The image displays three side-by-side screenshots of the Care Beacon mobile application, showing different sections of the interface.

Screenshot 1: Patient Story

Top bar: 8:00 PM, 100% battery, InVision WiFi.

Header: Our Child, Care Beacon.

Buttons: Patient Story (selected), Family Journal.

Section: Zachary ("Zac") Ellis, Apr 14, 2010.

Image: A young boy wearing a blue shirt and a black helmet, smiling and riding a bicycle.

Buttons: EDIT, MY STORY.

Text: Zac is our beloved and happy four year old son. He in turn loves his mom, dad, sister, and grandparents. Shortly after Zac's birth, we noticed that he was having difficulty breathing and was not moving his limbs as we might expect. At 8 weeks old and after weeks of testing on doctors diagnosed him with a combination neuromuscular issues coupled with respiratory problems. He's been in and out of the hospital.

Bottom navigation: Our Child, Timelines, Current Medical, Messages (3 notifications), More.

Screenshot 2: Medical Care

Top bar: 8:00 PM, 100% battery, InVision WiFi.

Header: Medical Care, Care Beacon.

Buttons: Care Team Contacts, Active Medications, DME Orders, PDN Agency, Therapy.

Section: CHRONIC CONDITIONS.

Section: Degenerative Neuromuscular Disorder.

Text: Age at onset: 1 mo, Recent notes: 1, Recent labs: 1, Other provider visit: June 6, 2016.

Text: VIEW DETAILS.

Text: Chronic Respiratory Insufficiency & Hypoxia.

Bottom navigation: Our Child, Timelines, Current Medical, Messages (3 notifications), More.

Screenshot 3: Messages

Top bar: 8:00 PM, 100% battery, InVision WiFi.

Header: Manage, Messages, Care Beacon.

Section: Home Care Nurse (11:04 AM): Yes Zac was able to handle his meal much better today.

Section: Specialist 1 & Specialist 2 (9:45 AM): Yes, Swallow Study has now been scheduled and should be complete...

Section: School Nurse (4:23 PM): Agree, we will let you know how that approach works tomorrow.

Section: DME Representative (Yesterday): Glad you are back home, we will resume normal shipments startin...




Section: CCC NCM & Family (Yesterday): See you in a few days!

Section: ENT & CCC NCM (Yesterday): Looking for the date on that most recent test, will follow up in later to...

Section: Therapist (Last Week): Correct, thanks for checking!

Bottom navigation: Our Child, Timelines, Current Medical, Messages (3 notifications), More.

Mobile application



Recent: ER & Hospitalization June 23-25, 2016Insurance Change: Family Plan of Texas, Thu June 23, 2016Upcoming Visit: CCC, Thu July 21, 2016

Zachary ("Zac") Ellis

[ADD NOTE](#)

DOB: January 12, 2012

Languages: Bilingual Spanish / English (no interpreter needed)

Provider Summary: Zac is 4 year old boy with degenerative neuromuscular disorder, dysphagia and worsening chronic respiratory insufficiency and hypoxia requiring oxygen during sleep. Child has required 4 hospitalizations over the last 6 months. Zac is exclusively fed by gastrostomy tube.

Last updated by Dr. Name Apr 7, 2016

My Family

[SEND MESSAGE](#)

Mom (34 yr)

Madeline "Maddie" Rollings-Ellis



Dad (38 yr)

Roberto Ellis



Sister (3 yr)

Amelia Ellis



Pet

Superman - hamster



Grandmother (67 yr)

Helena Rollings

Partial Summary Current Medical Situation



Degenerative Neuromuscular Disorder
Age at onset: 1 mo



Chronic Respiratory Insufficiency & Hypoxia
Age at onset: 2 mo



Epileptic Spasms, Infantile Spasms
Age at onset: 3 mo

[10 Medical Conditions](#)[8 Active Medications](#)[View Current Medical Situation](#)[Overview](#)[Family Journal](#)[Preventive](#)[PON](#)[Therapy](#)[DME](#)[School](#)[Pharmacy](#)

 [Family Completed Items for Upcoming Well-check:](#) (4 topics) 1. Shared seizure log: "We are wondering why there was a spike in activity... [Read More...](#)

 [Child Life Notes:](#) Prone to biting, afraid of the blood pressure cuff, calmed by ~~surprise~~ singing 'Frozen' theme.

Family Story: Zac is our beloved and happy four year old son. He in turn loves his mom, dad, sister, and grandparents. Shortly after Zac's birth, we noticed that he was having difficulty breathing and would seize minutes his tummy as was might happen. At 8 weeks old and after weeks of

HOME ADDRESS

2011 E 6th St, Ste. 3B Austin, TX 23456





Zachary ("Zac") Ellis

DOB: January 12, 2012

Medical Diagnoses

Chronic Conditions

Degenerative Neuromuscular Disorder

Age at onset: 1 mo
Recent notes: 1
Recent labs: 1
Other provider visit: June 6, 2016

[VIEW DETAILS](#)

Chronic Respiratory Insufficiency & Hypoxia

Age at onset: 2 mo
Recent notes: 1 1
Recent labs: 3
Upcoming CCC visit: Aug 12, 2016

[VIEW DETAILS](#)

Epileptic Spasms, Infantile Spasms

Age at onset: 3 mo
Recent notes: 4
Recent labs: N/A
Recent CCC visit: May 4, 2016

[VIEW DETAILS](#)

Dysphagia

Age at onset: 1 yo
Recent notes: 2
Recent labs: N/A
Recent CCC visit: May 4, 2016

[VIEW DETAILS](#)

Acute Conditions

- Ear infection: April 10, 2016
- Upper respiratory illness: May 22, 2016

Behavioral Conditions

- ADHD

Developmental Conditions Review

Behavioral Conditions

Active Medications (8)

Albuterol Sulfate 2.5 mg/3 mL (0.083 %) solution for nebulization

Brown MD, Mark
Ordered: 5/2/2015
Last Filled: 7/9/2016
6 refills good until 12/17
Inhale 3 mL, twice a day by nebulization route routinely for airway clearance and q 4 hours PRN.

Pulmicort 1 mg/2 mL suspension for nebulization

Smith MD, Stephanie
Ordered: 8/24/2015
Last Filled: 7/9/2016
6 refills good until 12/17
INHALER 1 VIAL VIA NEBULIZER TWICE DAILY

omeprazole 2mg/ml

Brown MD, Mark
Ordered: 5/2/2015
Last Filled: Overdue for Refill
2 refills good until 9/16
Give 5ml BID via Gtube

Cetirizine 5 mg/5 mL oral solution

Brown MD, Mark
Ordered: 5/2/2015
Last Filled: Overdue for Refill
2 refills good until 9/16
5ml via GT once a day pm allergy symptoms

Feeding & Dietary Information

NEW Updated: August 1, 2016

CLINIC NOTES:

- Exclusively fed by G-tube
- Micky button (4fr, 1.4cm)
- Pedisure (1 cal/cc) takes Boz four times a day by gravity bolus
- Diet well tolerated.
- Normal growth parameters (See Growth chart)

Last updated by CCC on June 15, 2016

FAMILY COMMENTS:

- Table food all by mouth
- Drinks, 2 glasses of milk a day
- Does not like vegetables

Last updated by Mom on June 27, 2016

Learning & Communication

- I am working with the speech therapist to improve my communication. I can point to my word board to communicate.



Family Video
How I express happiness



Family Video
How I express pain



Family Video
How I express hunger



Personal Information

NEW Updated: July 29, 2016

- I like when my parents read me story books
- I love to watch UT Football
- I wear orange every day and his room is full of Longhorns
- I know each UT player by name
- My sister plays piano and sometimes I try to hum or sing along

Goals, Hopes, Fears & Past Trauma

- Goals is for Zac to have the maximum function possible to enjoy life
- Hospitalizations tend to be very traumatic for the family so we would like to minimize them as much as possible
- We are most worried about progression of his respiratory condition and further complications
- Our family has had many experiences related to medical errors and difficulty navigating the healthcare system.
- Zac has suffered many setbacks and prolonged hospitalizations in the past some of these could have been avoided with good communication of his team.

CareWindow Patient Story Current Situation **Medical Timelines** Message Center 16 Profile | Logout

Calendar Timeline | View All Timelines

Zachary ("Zac") Ellis DOB: January 12, 2012

Calendar Timeline Jun 23 – Jun 29 Search...

All Conditions All Events < | Viewing Today | > 12 Months | 1 Month | 1 Week

Thu 6/23/16	Fri 6/24/16	Sat 6/25/16	Sun 6/26/16	Mon 6/27/16	Tue 6/28/16	Wed 6/29/16 TODAY
ED Visit	Hospital Admission			RX Pickup! (2)	School Nurse	Seton CCC Visit
CircleBeacon Sent	Radiology		RX Refill Missed (3)			
Family Note Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***	ED Discharge Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***			RX Issue! (9) Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***	Therapy Note Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***	Family Note Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***
Insurance Change Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***	Lab Results Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***					DME Delivery (11) Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***
	Family Recording Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do... ***					

Contacts:

Rahel Berhane, MD

- RXBerhane@seton.org

Anjum Khurshid, MD PhD

- akhurshid@gmail.com



Rick Hansen Institute
Institut Rick Hansen

Consumer Engagement in Spinal Cord Injury Research at the Rick Hansen Institute

John Chernesky
October 21, 2016



The Reality of SCI

[THE REALITY OF SCI]

Spinal cord injuries (SCI) have a devastating impact on the health and well-being of individuals. Many would categorize SCI as one of the greatest survivable catastrophes experienced by a human being. Health care services for people who sustain a SCI are highly specialized and complex. Regardless of cause or age at injury, SCI has far reaching consequences for individuals and their families.

SOME FACTS ON SCI IN CANADA

People living with SCI in Canada


86,000
121,000 projected by 2030

Number of new cases of SCI each year

4,300
5,800 a year by 2030

Traumatic SCI occurs most commonly in males between the ages of

20 ➤ 29
years old



Sources: Dryden et al. 2004, "Utilization of health services following spinal cord injury: a six year follow-up study".
Nieminen et al. 2012, "Incidence and prevalence of spinal cord injury in Canada: a national perspective".
Krueger et al. 2013, "The economic burden of traumatic spinal cord injury in Canada".
Urban Futures Institute, 2010, "The Incidence and Prevalence of Spinal Cord Injury in Canada".

COST OF TRAUMATIC SCI

Financial care requirements over a lifetime for each individual can vary from

\$1.5 Million
PARAPLEGIC

\$3.0 Million
QUADRIPLEGIC

The estimated economic cost of traumatic SCI for newly injured Canadians is

\$2.7 Billion
PER YEAR

health care, equipment and modifications, long-term care. Costs are even greater when including those with chronic injuries.

CANADIANS WITH TRAUMATIC SCI

COMPARED TO THE GENERAL POPULATION

Are re-hospitalized

2.6X
more often

Require contact with a physician

2.7X
more often


Require home care services

30X
more hours

Have a far shorter life expectancy
15 ➤ 30
fewer years

- C1
- C2
- C3
- C4
- C5
- C6
- C7
- T1
- T2
- T3
- T4
- T5
- T6
- T7
- T8
- T9
- T10
- T11
- T12
- L1
- L2
- L3
- L4
- L5

spinal cord injury + your body



SCI:

- **Affects every physiological system**
- **7 to 30 secondary complications**
 - Average is 15
- **Chronic and complex condition**

Barriers to Participation in SCI Research

- * Heterogeneity
- * Acute Interventions (< 12 hours)
- * Lack of Urgency
- * Autonomic Dysfunctions
- * Secondary Complications
- * Mobility
- * Income Disparity

A world
without paralysis
after spinal cord injury.

To lead collaboration

Across the global spinal cord injury community by providing resources, infrastructure and knowledge; and to...

- * identify, develop, validate and accelerate the translation of evidence and best practices to reduce the incidence and severity of paralysis after SCI,
- * improve health care outcomes,
- * reduce long-term costs, and
- * improve the quality of life for those living with SCI

RHI's Core Programs



- * Founded by Rick Hansen
- * Consumers on Board of Directors
- * Advisory Committees
- * Priority setting, strategic planning and project review
- * Praxis 2016



Engaging people with SCI in research and helping them make evidence-based decisions about their health

SERVES

- Persons with SCI, their family and friends, as well as consumer-focused community organizations and advocacy groups

OBJECTIVES

- Provide resources and tools to help answer people's most critical questions about their injury
- Promote self-management of health to reduce the incidence of secondary complications
- Identify activities and opportunities to engage consumers and increase involvement in research

- * SCIRE Community
- * Self Management
- * Patient-partners in research
- * Education to newly injured
- * Central patient recruitment
- * Video's in partnership with Comm. Org's
- * Advocating for change in practice to improve clinical care



Questions?



John Chernesky

Rick Hansen Institute
6400-818 West 10th Avenue
Vancouver, BC Canada V5Z 1M9

rickhanseninstitute.org
jchernesky@rickhanseninstitute.org
604 827 2428

 /RickHansenInstitute

 @rhinstitute

PCORI and the ripple effect: Patient communities



Lorraine Johnson, JD, MBA

Patient Engagement Advisory Panel, Patient Centered Outcomes Research Institute
Co-Chair Consumers United for Evidence-Based Healthcare; CEO, LymeDisease.org


October 21, 2016 PCORI PEAP

PCORI and patient-centered research




- Patient engagement rubric
- Patient compensation rubric
- Top 10 research priorities of patients
- PCORnet—patient-powered big-data research

Lyme disease is a research disadvantaged



The democratization of science





IMAGINE A WORLD where people with Lyme disease are diagnosed and treated correctly and go back to living their lives.

YOU CAN BE PART OF MAKING THIS HAPPEN



MyLymeData


To learn more, visit lymedisease.org/mylymedata

MyLymeData expects to gather more data about Lyme disease than any research study has done before

- First national large-scale longitudinal study of patients with Lyme disease
- Over 5,100 patients are enrolled, (Fastercures over 5,000 = top 10% of patient powered registries)
- Patient centered
- Phase I was launched in November 2015
 - Exposure, diagnosis, labs, sick/well status, and quality of life impairment.
- Phase 2 was launched in October 2016
 - 3 month follow-up
 - SF-36
 - General health history
 - Decedent survey


Open publication of data or a trusted intermediary role

2.3 De-Identification Data Flow Model



How effective are different alternative treatments?

Not Effective ← → Effective



Not Effective Unsure

Mod. Effective Very Effective

19
APR
2016


LYMEPOLICYWONK: Misdiagnosis of Lyme disease as MS – MyLymeData Quick Bytes



neurologic diseases?

This is the first in what I hope will be a series of “quick bytes” (2-minute videos) of some of the preliminary results we are getting from MyLymeData. You can choose to watch the video or read the blog. Today I am going to talk about what we are finding with misdiagnosis. Most of us know that Lyme disease is commonly misdiagnosed as chronic fatigue, fibromyalgia, or depression. But did you know that 20% are misdiagnosed with incurable progressive

Approximately 20% of chronic Lyme patients are initially misdiagnosed with neurologic disease.



BE PART OF THE CONVERSATION

Let us know your experience.

Have you been diagnosed with Lyme disease by a healthcare provider?


- Yes
- No
- Unsure

Were you initially misdiagnosed with a progressive neurological disease?

- Yes
- No
- Unsure
- Not applicable

What neurologic disease were you initially misdiagnosed with?

Setting Research Priorities for Lyme disease



The James Lind Alliance

Priority Setting Partnerships

Tackling treatment uncertainties together

- Based loosely on James Lind Alliance process but quick and broader—internet based large scale surveys
 - Conference of researchers, clinicians, and patients generated 20 questions
 - MyLymeData participants vote on this and suggest additional research priorities
 - Broader community invited to then vote on these

Using PCORI rubrics to jointly apply for grants



National Science Foundation
WHERE DISCOVERIES BEGIN

Contact | Help

Search



NSB

Research Areas

Funding

Awards

Document Library

News

About NSF

Funding

About Funding

Browse Funding Opportunities A-Z

Due Dates

Find Funding

Merit Review

Policies and Procedures

Preparing Proposals

Recent Opportunities

Transformative Research

Home > Funding

Email Print Share

About Funding

The National Science Foundation funds research and education in most [fields of science and engineering](#). It does this through grants, and cooperative agreements to more than 2,000 colleges, universities, K-12 school systems, businesses, informal science organizations and other research organizations throughout the United States. The Foundation accounts for about one-fourth of federal support to academic institutions for basic research.

NSF receives approximately 40,000 proposals each year for research, education and training projects, of which approximately 11,000 are funded. In addition, the Foundation receives several thousand applications for graduate and postdoctoral fellowships.

The agency operates no laboratories itself but does support National Research Centers, user facilities, certain oceanographic vessels and Antarctic research stations. The Foundation also supports cooperative research between universities and industry, US participation in international scientific and engineering efforts, and educational activities at every academic level.

Presenting at conferences to engage researchers

Using a New Patient-Powered Research Tool to Answer Critical Questions about Lyme Disease

Lorraine Johnson, Phyllis Mervine, Melissa Potter
LymeDisease.org, Los Angeles, CA USA


Introduction

MyLymeData is a patient registry developed by LymeDisease.org that enables patients to pool longitudinal healthcare data. Since its launch in November 2012, 2,223 patients have enrolled.

The 4,214 participants in this sample included 125 residents clinically diagnosed with Lyme disease who completed the survey. A subgroup that characterized themselves as "well" (32%), or "well" (14%) and identified the stage of their disease at diagnosis (1,387) was analyzed.


We compare the recovery rate of the 1154 diagnosed early with the 795 diagnosed late (untreated for 6 months or more after onset).

Sample & exclusions algorithm



Supporting Diagnostic Tests

Most patients (70%) enrolled in MyLymeData report their diagnosis is supported by positive lab tests. 27% do not have supporting evidence and 3% responded "Don't know."



Acknowledgments

The authors would like to acknowledge the patients who participated in MyLymeData for their time in a conference. We would also like to thank Dr. Daniel R. Wallace, Dr. Robert Shmerling, Dr. Alan G. Tashiro, Dr. Michael J. Johnson, and the International Society of Lyme Disease and Associated Diseases Society for sharing their information on physician referrals for Lyme disease in Colorado.

Further Information

For further information about this poster session or MyLymeData, please contact Lorraine Johnson, PhD, LymeDisease.org. MyLymeData has many resources in many ways, for example, by providing patient registry data, collecting survey data, recruiting patients for studies, and providing long-term follow-up for complicated trials.

Results

Patients diagnosed early were more likely to be "well" (32%) than patients diagnosed late (9%). 54% a large proportion of patients diagnosed early (32%) and almost all of those diagnosed late (91%) remained ill. These findings suggest the importance of early diagnosis and the need to develop improved treatment regimens for both early and late Lyme disease.

Causes of diagnostic delay



Diagnostic delays were associated with false negative lab tests (27%), positive lab tests classified as "false positive" (20%), and missed diagnostic opportunities when healthcare providers failed to evaluate the patient because "there is no Lyme here."

Estimates in Colorado suggest the true incidence prevalence of Lyme disease is far greater than previously believed clinical diagnosis based on predictive models, such as Taylor-Thornicroft. CDC surveillance data reports underestimate actual incidence by a factor of 12 nationwide.

CDC News: Lyme Disease Diagnosis Difficult in Colorado
"The common belief is that the disease does not exist here, but patients infected say otherwise."

Indicators of true incidence of Lyme disease in Colorado very unlikely.

Indicator	# of Cases
522 cases (2014)	12
120x multiple of 522 cases	132
1102 cases (2014)	22
1102 cases (2014)	22
1102 physician-related requests (2014-15)	742
Centers for Disease Control (2014)	840
Centers for Disease Control (2014-15)	840

CBS News Denver learned Lyme disease is more than 12 times more challenging to being diagnosed in Colorado, where people say "We don't have Lyme in Colorado, so you don't need to worry."

Conclusions

Lyme disease patients have significantly better outcomes when they are diagnosed early. Reducing barriers to early and improving treatment would be a positive health benefit. Physicians should be advised to test for Lyme disease and refer to Lyme disease specialists. Patients with Lyme disease are more likely to be promptly treated without lab testing as false negative test results of **CDC test** and **PCP**. Positive test results should not be disseminated in symptomatic patients. Public health officials should be aware that CDC case numbers may greatly underestimate the true incidence of Lyme disease in an area. Finally, even in areas where Lyme disease is less common, asymptomatic patients need to be tested and accurately diagnosed to prevent unnecessary suffering. It is time to focus on prompt diagnosis and early intervention to prevent chronic Lyme disease from developing.

Limitations and Future Research

This analysis is correlational and cannot determine cause and effect. We do not examine treatment effects. Future studies might explore the associations between treatment and restoration of health.

Literature cited

- 1. CDC. Lyme Disease. www.cdc.gov/lyme/disease/index.html
- 2. MyLymeData. www.lymedisease.org/MyLymeData.html
- 3. Shmerling, R. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 4. Wallace, D. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 5. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 6. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 7. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 8. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 9. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 10. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 11. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 12. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 13. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 14. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 15. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 16. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 17. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 18. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 19. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 20. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 21. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 22. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 23. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 24. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 25. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 26. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 27. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 28. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 29. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 30. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 31. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 32. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 33. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 34. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 35. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 36. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 37. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 38. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 39. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 40. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 41. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 42. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 43. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 44. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 45. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 46. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 47. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 48. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 49. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 50. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 51. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 52. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 53. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 54. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 55. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 56. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 57. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 58. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 59. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 60. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 61. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 62. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 63. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 64. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 65. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 66. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 67. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 68. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 69. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 70. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 71. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 72. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 73. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 74. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 75. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 76. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 77. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 78. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 79. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 80. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 81. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 82. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 83. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 84. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 85. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 86. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 87. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 88. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 89. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 90. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 91. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 92. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 93. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 94. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 95. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 96. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 97. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 98. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 99. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 100. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 101. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 102. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 103. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 104. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 105. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 106. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 107. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 108. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 109. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 110. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 111. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 112. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 113. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 114. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 115. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 116. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 117. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 118. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 119. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 120. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 121. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 122. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 123. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 124. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 125. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 126. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 127. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 128. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 129. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 130. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 131. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 132. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 133. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 134. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 135. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 136. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 137. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 138. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 139. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 140. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 141. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 142. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 143. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 144. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 145. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 146. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 147. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 148. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 149. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 150. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 151. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 152. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 153. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 154. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 155. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 156. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 157. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 158. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 159. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 160. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 161. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 162. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 163. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 164. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 165. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 166. Johnson, L. www.ncbi.nlm.nih.gov/pmc/articles/PMC3500033/
- 167. Johnson, L. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/

Physician engagement

[BECOME A MEMBER](#)[LOGIN](#)[HOME](#) [LYMETIMES](#) [CURRENT ISSUE](#) [ARCHIVES](#) [RESOURCES](#) [PHYSICIANS](#) [MEMBERS](#) [ABOUT US](#)

PHYSICIAN WAITING ROOM PROGRAM

The Waiting Room Program is a free resource for clinician waiting rooms. more text here about value

[LEARN MORE](#)

Is it business as usual or do we “have the chance to turn the world **upside down** just a bit?”

Dr. Harlan Krumholz, PCORI






lym~~e~~ disease.org

A Consolidated Model of Patient Engagement

Megan Lewis, PhD

Director, Patient and Family Engagement Research Program
Center for Communication Science



Why is a Consolidated Model Needed?


- A plethora of models creates:
 - Conceptual confusion
 - Problems with measurement and defining relevant outcomes
 - Barriers to capitalizing on the potential synergy of Patient Engagement within or across domains
- A consolidated model facilitates:
 - Common definitions
 - Specific and relevant intermediary and long-term outcomes
 - Capturing a range of mechanisms that can be examined in comparative effectiveness research (CER)



Why is a Consolidated Model Needed? (cont.)

- A consolidated model can:
 - Facilitate comparison of findings across studies
 - Speed translation of evidence-based research to practice
 - Ensure patients, family members, and stakeholders involved in patient-centered endeavors understand the larger picture
 - Ensure that researchers involved in specific areas of patient engagement research see the “sight line” across different domains

Search Process for PE Models



Overlaps and Gaps Found During Literature Search

- Overlap
 - Most models focus on 1 or 2 domains:
 - Self-care
 - Health care
 - Organizational design and governance
 - Health policy
 - Health research
 - Most models focus on self-care or health care
 - Most models focus on processes or “how” it should work
- Gaps
 - Models do not include all relevant domains
 - Intervention development and implementation domain was missing
 - No systematic inclusion of family engagement
 - Outcomes not systematically specified
 - “Engagement” outcomes not defined systematically as intermediary outcomes
 - Some models do not reflect current standards of practice (e.g., use of health IT)

Domains and Subdomains

Patient Engagement Model: Domains and Subdomains



Self-Care

- Practice preventive and health-promoting behaviors
- Seek and use health information
- Manage health conditions



Healthcare

- Seek high quality care
- Organize healthcare
- Manage health information and health records
- Communicate with healthcare professionals
- Participate in decision making
- Promotes own safety in the healthcare setting



Design and Implementation of Health Programs

- Participate in formative research
- Establish program priorities
- Determine program design
- Develop program materials
- Disseminate program information



Organizational Design and Governance

- Participate in governing and advisory bodies
- Develop organizational priorities and strategies
- Make decisions about organizational design and governance



Health Policy

- Develop legislative regulation and funding priorities
- Develop environmental and social plans
- Implement policies




Health-Related Research

- Train for role in research
- Develop analysis plan
- Select research topics
- Develop study protocols
- Establish study ethics
- Implement policies
- Interpret results
- Translate study findings
- Create conceptual framework
- Disseminate study findings

Consolidated Model of Patient Engagement

Domains and Outcomes of Patient Engagement



Delphi Panel Participants

- 20 participants approached based on experience in the different domains of patient engagement.
- Included researchers, clinicians and patient advocates.
- In total, 19 experts agreed to participate.
 - Gender:
 - 13 female and 6 male
 - Background:
 - 8 from academic medical schools or university departments
 - 5 from a non-profit organization
 - 3 are independent patient advocates
 - 3 are from independent research organizations

Delphi Study Overview

- Delphi study composed of three surveys to reach consensus on model domains, subdomains, and outcomes and their definitions
- All responses anonymous
- In each round, participants
 - (1) selected to include or exclude domains and subdomains,
 - (2) indicated whether they agreed with the definitions of subdomains and domains,
 - (3) indicated whether they agreed with the engagement outcomes included in the original model, and
 - (4) provided feedback on intermediate and longer term outcomes, as shown below.

Overview of Surveys


Survey 1	Survey 2	Survey 3
<ul style="list-style-type: none">• Domains to include• Domain definitions• Subdomains to include	<ul style="list-style-type: none">• Domain definitions• Subdomain definitions• Engagement outcomes	<ul style="list-style-type: none">• Domain definitions• Subdomain definitions• Intermediate outcomes• Longer term outcomes

Results: Domains and Subdomains

- After Survey 1:
 - 97% overall agreement on inclusion of domains.
 - 58% agreement on definitions across the 6 domains.
- After Survey 2:
 - 90% agreement on definitions across the 6 domains.
 - 83% agreement on definitions across the subdomains.
- Survey 3 is ongoing:
 - Preliminary results suggest >90% on definitions across the 6 domains.

Results: Engagement Outcomes

- Developed a framework for how engagement outcomes could be conceptualized
 1. **Behavioral Capabilities:** Having the knowledge and skills to perform a given behavior
 2. **Self-efficacy:** An individual's confidence in performing a particular behavior and overcoming barriers to that behavior
 3. **Attitudes/Beliefs:** An individual's values and perceptions about an issue
 4. **Behaviors:** Carrying out a particular behavior



Implications for Patient Involvement

- Help prioritize the ways we involve patients in research and identify gaps
- If patients are going to be involved in research, we need to develop measures of engagement



Study Team and Support

- Katherine Treiman
- Catherine Slota
- Brittany Zulkiewicz
- Nupoor Kulkarni
- Supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001111

Discussion & Wrap-up



*Thank you
and
Safe Travels!*